Treatment patterns of venous thromboembolism in a real-world population: The Q-VTE study cohort

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 795-802

  Tagalakis, Vicky ^a   Patenaude, Valérie ^a   Kahn, Susan R ^a   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Deep vein thrombosis; Pulmonary embolism; Treatment patterns; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DANAPAROID; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CANADA; CONTUSION; DEATH; DEEP VEIN THROMBOSIS; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHILD; COHORT ANALYSIS; COMPLICATION; INFANT; PRESCHOOL CHILD; PULMONARY EMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PULMONARY EMBOLISM; QUEBEC; VENOUS THROMBOEMBOLISM; VITAMIN K; YOUNG ADULT;

EID: 84908205835     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.07.002     Document Type: Article

References (27)

1. Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
2. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25.
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
4. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism Study. A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006;21:722-7.
5. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9.
6. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013;129:832.e13-21.
7. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
8. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-6.
9. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Investigators of the "Durée Optimale du Traitement anti Vitamines K" (DOTAVK) Study, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001;103:2453-60.
10. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Duration of Anticoagulation Trial Study Group, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
11. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
12. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205.
13. Hansson PO, Sorbo J, Eriksson H. Recurrent Venous Thromboembolism after Deep Vein Thrombosis. Incidence and Risk Factors. Arch Intern Med 2000;160:769-74.
14. Labropoulos N, Spentzouris G, Gasparis AP, Meissner M. Impact and clinical significance of recurrent venous thromboembolism. Br J Surg 2010;97:989-99.
15. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, American College of Chest Physicians, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):e419S-94S.
16. Statistics Canada. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures (CCP) (Catalogue 82-562E). Ottawa: Minister of Industry, Science and Technology; 1993.
17. Volume Three - Canadian Classification of Health Interventions (CCI) - Tabular List. Ottawa: Canadian Institute for Health Information; 1992.
18. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-8.
19. Cohen A, Martinez C, Wallenhorst C, Bamber L. Vitamin K antagonist treatment patterns and persistence after venous thromboembolism in non-cancer patients: VTE Epidemiology Group (VEG) Study. [abstract] , XXIV ISTH Congress. 2013 July 2. Amsterdam, NL; 2013.
20. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299-304.
21. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-67.
22. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979-87.
23. Regie de l'assurance maladie du Quebec - Statistics annuelles; 2006.
24. Sule AA, Chin TJ, Handa P, Earnest A. Should symptomatic, isolated deep vein thrombosis be treated with anticoagulation? Int J Angiol 2009;18:83-7.
25. Heleen van Ommen C, Heijboer H, Buller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: A prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-81.
26. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):e691S-736S.
27. Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 2010;27:623-33.